MEK inhibitors

Trametinib: new treatment for recurrent LGSOC

Targeting oncogenes in NSCLC

Heating up a tumor: modulating the immunoscore

Development of novel treatments in melanoma patients with BRAF mutations

News from ASCO 2016 for melanoma

The developments of genetic testing and personalized cancer vaccines for patients with skin cancer

Using biomarkers to predict response to combination therapies in BRAF-mutant melanoma

Neoadjuvant therapy with trametinib and dabrafenib in high risk resectable BRAF-mutant melanoma

Combined treatment with BRAF and MEK inhibitors in metastatic melanomas with BRAF mutations

Neoadjuvant therapy in bulky Stage III melanoma

SECOMBIT – determining the order of sequential therapies in metastatic melanoma with BRAF mutations